Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: Proceed trial (KCSG BR 11-01)

Cancer Research and Treatment

Volumn 51, Issue 1, 2019, Pages 43-52

  Park, In Hae ^b   Im, Seock Ah ^c   Jung, Kyung Hae ^d   Sohn, Joo Hyuk ^e   Park, Yeon Hee ^f   Lee, Keun Seok ^b   Sim, Sung Hoon ^b   Park, Kyong Hwa ^g   Kim, Jee Hyun ^h   Nam, Byung Ho ^a,b   Kim, Hee Jun ⁱ   Kim, Tae Yong ^c   Lee, Kyung Hun ^c   Kim, Sung Bae ^d   Ahn, Jin Hee ^d   Lee, Suee ^j   Ro, Jungsil ^b  

^a AIDS Research Institute   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Seoul National University Bundang Hospital   (South Korea)

ⁱ Chung Ang University College of Medicine   (South Korea)

^j Dong A University College of Medicine   (South Korea)

more..

Author keywords

Capecitabine; Clinical trial; Irinotecan; Metastatic breast cancer; Progression free survival

Indexed keywords

CAPECITABINE; IRINOTECAN; LOPERAMIDE; MAGNESIUM OXIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS; VOMITING; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED-RING COMPOUNDS; CAPECITABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IRINOTECAN; MIDDLE AGED; PROGRESSION-FREE SURVIVAL; QUALITY OF LIFE; TAXOIDS; TREATMENT OUTCOME;

EID: 85059913884     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2017.562     Document Type: Article

References (22)

1. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)dagger. Ann Oncol. 2014;25: 1871-88.
2. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3:430-40.
3. Pizzolato JF, Saltz LB. The camptothecins. Lancet. 2003;361: 2235-42.
4. Ichikawa W, Takahashi T, Suto K, Yamashita T, Nihei Z, Shi-rota Y, et al. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Br J Cancer. 2004;91:1245-50.
5. Guo Y, Shi M, Shen X, Yang C, Yang L, Zhang J. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. Clin Colorectal Cancer. 2014;13:110-8.
6. O'Connor T, Rustum Y, Levine E, Creaven P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol. 2008; 61:125-31.
7. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22:2849-55.
8. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, et al. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010;21:493-7.
9. Stathopoulos GP, Tsavdaridis D, Malamos NA, Rigatos SK, Kosmas C, Pergantas N, et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol. 2005;56:487-91.
10. Lee KS, Park IH, Nam BH, Ro J. Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer. Invest New Drugs. 2013;31:152-9.
11. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.
12. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res. 2004;13:863-8.
13. Jassem J, Carroll C, Ward SE, Simpson E, Hind D. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer. 2009;45:2749-58.
14. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist. 2006;11 Suppl 1:42-51.
15. Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C, et al. Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol. 2012;138:221-9.
16. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-23.
17. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26: 3950-7.
18. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28:3256-63.
19. Perez EA, Awada A, O'Shaughnessy J, Rugo HS, Twelves C, Im SA, et al. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicen-tre, phase 3 trial. Lancet Oncol. 2015;16:1556-68.
20. Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014;74:1125-37.
21. Twelves C, Cortes J, O'Shaughnessy J, Awada A, Perez EA, Im SA, et al. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: results from the randomised phase III BEACON trial. Eur J Cancer. 2017;76: 205-15.
22. Cortes J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, et al. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017;165:329-41.